Focal Segmental Glomerulosclerosis
55
17
19
23
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
12 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
12.7%
7 terminated out of 55 trials
76.7%
-9.8% vs benchmark
11%
6 trials in Phase 3/4
52%
12 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (55)
NEPTUNE Match Study
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Genetic Markers for Focal Segmental Glomerulosclerosis
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
taVNS for FRNS in Children
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
AMPK-activation by Metformin in FSGS: AMP-FSGS
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
Atrasentan in Patients With Proteinuric Glomerular Diseases
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome